Abbott (ABT) Q3 2026 Earnings Call Transcript

Abbott reported Q3 2026 comparable sales growth of 7% and adjusted EPS of $1.42, up 9% year over year and in line with guidance; adjusted gross margin expanded 140 bps to 57.2%. The company plans to separate its nutrition business, with approximately $8.5 billion in annual sales, into an independent public company by the end of 2027, and expects the remaining Abbott portfolio’s sales growth to accelerate by 50–100 bps after separation. Full-year comparable sales guidance is approximately 6.0% and adjusted EPS guidance is $5.50–$5.55; management cited near-term EP headwinds and international diabetes pricing pressure, while a July cybersecurity event reduced cancer diagnostics growth by about 1 percentage point in the quarter.

Analysis

The key valuation question is not the announced nutrition spin itself, but whether Abbott can convert a cleaner portfolio mix into durable organic growth while absorbing separation costs and preserving capital flexibility. The projected post-spin margin uplift is arithmetic portfolio mix, not evidence of immediate operating improvement; the new company’s debt-funded distribution to Abbott also shifts leverage and may constrain the nutrition business’s ability to invest or pursue acquisitions. Treat the claimed growth and margin benefits as management targets until pro forma filings clarify stranded costs, debt allocation, and standalone cash generation.

Near term, the more consequential signal is Abbott’s cautious top-line posture: international CGM price concessions may defend share but dilute revenue quality, while delayed reimbursement expansion leaves adoption dependent on commercial channels. EP order deferrals around the LAA launch could temporarily mask PFA momentum; if clinicians delay broader purchasing pending data or product availability, growth may take longer to recover than management expects. Cyber disruption also shows how connectivity dependence can interrupt diagnostics workflows and create recurring operational risk—not just a one-quarter sales blip. Exact Sciences’ reported contribution should be judged on comparable growth, integration execution, and profitability rather than acquired sales.

Over 1–3 months, track EP orders and diabetes-care pricing/volume; over 6–18 months, watch CMS reimbursement, product launches, and spin terms. Contrarian view: the spin may not produce a near-term rerating if investors discount the new company’s consumer-facing execution needs and unresolved liability allocation. No standalone EXAS trade follows from this call; its integration is now an Abbott execution issue.

Key Decisions for Investors

• ABT: Prefer staged long exposure on post-call weakness rather than chasing the strategic-announcement reaction. The upside case is improving portfolio mix plus launches; the near-term counterweight is softer CGM growth and EP timing. Reassess if comparable sales guidance is cut again or operating-margin expansion stalls.
• Do not capitalize the projected 50–100 bp growth acceleration or margin uplift as delivered value yet. Before assigning a spin premium, verify separation filings for stranded costs, debt allocation, dividend mechanics, and responsibility for legacy liabilities; the end-2027 target leaves substantial execution time.
• Set alerts on CGM unit/price trends and EP order recovery. The thesis weakens if pricing concessions fail to stabilize share, if LAA-related delays persist after Amulet 360 availability, or if upcoming clinical evidence disappoints; CMS reimbursement timing remains upside optionality, not a base-case catalyst.
• Avoid treating acquired diagnostics sales as organic acceleration. Monitor comparable cancer-diagnostics growth, customer connectivity restoration, and Exact Sciences integration economics; further cyber interruptions or deteriorating comparable growth would challenge the acquisition-value thesis.